Achieving optimal uptake of TB preventive treatment for rifampin-resistant and/or multidrug-resistant TB.

With clinical trials establishing the efficacy of levofloxacin preventive treatment for exposure to multi-drug resistant/rifampin-resistant TB, national programs are in the process of updating their guidelines for programmatic roll-out. However, national programs need to carefully consider contextual barriers and enablers to achieve optimal uptake of this preventive treatment for household and close contacts. Creating a patient-centered environment and engaging stakeholders across the spectrum of care will ensure equitable access and help to realise the full potential of this treatment.